{
    "clinical_study": {
        "@rank": "124340", 
        "acronym": "DREAM", 
        "arm_group": [
            {
                "arm_group_label": "DHP107 (oral paclitaxel)", 
                "arm_group_type": "Experimental", 
                "description": "DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy  in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum."
            }, 
            {
                "arm_group_label": "Taxol\u00ae (IV paclitaxel)", 
                "arm_group_type": "Active Comparator", 
                "description": "Taxol\u00ae (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the efficacy and safety of DHP107 (Oral\n      paclitaxel) in comparison to Taxol\u00ae(IV paclitaxel) in Patients With Metastatic or Recurrent\n      Gastric Cancer After Failure of 1st Line Chemotherapy With Fluoropyrimidine +/- Platinum."
        }, 
        "brief_title": "A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol\u00ae in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage IV Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. \u226520 years of age\n\n          2. Histologically or cytologically confirmed unresectable, recurrent or metastatic\n             gastric cancer\n\n          3. Failure of a first line therapy with fluoropyrimidine +/- platinum for metastatic or\n             recurrent disease.(Adjuvant chemotherapy is not considered as a first line\n             chemotherapy unless recurrence developed within 6 months of completion of adjuvant\n             therapy.)\n\n          4. Adequate bone marrow, liver and renal functions\n\n          5. INR \u2264 2.0\n\n          6. ECOG performance status \u2264 2\n\n          7. Neuropathy grade \u2264 1\n\n          8. Life expectancy of at least 3 months\n\n          9. Measurable lesion according to RECIST version 1.1 on CT scan\n\n         10. Written informed consent\n\n         11. Patients of child bearing age have to agree to the usage of adequate contraception\n             from before the registration to the study, during the participation period and 90\n             days after the end of treatment. Female of child bearing age has to show negative for\n             urin pregnancy test within 7 days from beginning of the start of administration.\n             Amenorrhea status has to be sustained for at least 12 months to be considered\n             non-pregnant in case of postmenstrual women.\n\n        Exclusion Criteria:\n\n          1. Major infectious disease, neurological disorder, or bowel obstruction.\n\n          2. Patients with CNS metastases(confirmed through brain imaging if there are symptoms)\n\n          3. Patient diagnosed with another cancer type (except non-melanoma skin cancer, cervical\n             cancer, or any other cancer that did not recur or metastasized for more than 5 years\n             and considered as complete remission can be registered)\n\n          4. Patient who received radiation therapy within past 2 weeks or who had major surgery\n             including organ resection within past 4 weeks from random assignment date\n\n          5. Patient with the history of failure to the taxane chemotherapy\n\n          6. Patient who need chronic concomitant use of P glycoprotein, immune suppressor, proton\n             pump inhibitor, or H2-receptor antagonist during the period of clinical trial\n\n          7. Chronic treatment using steroid (except oral, local injection, or for externally\n             applied) or other immune suppressor\n\n          8. Patient with myocardial infarction, congestive heart failure, arrhythmia showing\n             abrupt change in the ECG, severe or unstable angina, or other serious heart disease\n\n          9. Patient with other serious internal disease (chronic obstructive or chronic\n             inhibitory lung disease including shortness of breathe at rest due to all reasons,\n             uncontrollable diabetes and hypertension)\n\n         10. History of abuse of a drug or alcohol within 3 months\n\n         11. Lactating or pregnant women, or patient (or spouse) who has no intension of using, or\n             cannot use very effective mean of contraception\n\n         12. Patient who has or is suspected to have problem in bile acid secretion\n\n         13. Patient with active gastrointestinal bleeding, or taking oral anti- vitamine K (With\n             the exception of low dose of Warfarin and acetylsalicylic acide when INR\u22642.0)\n\n         14. History of serious hypersensitive reaction to the main ingredient or the excipient of\n             the investigational drug\n\n         15. History of being seropositive for HIV (HIV test is not a prerequisite).\n\n         16. Patients with gastrointestinal dysfunction or on enteral feeding\n\n         17. Other patients who are deemed inadequate to participate in the clinical trial by the\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "238", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839773", 
            "org_study_id": "107CS-3"
        }, 
        "intervention": [
            {
                "arm_group_label": "DHP107 (oral paclitaxel)", 
                "description": "Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "DHP107"
            }, 
            {
                "arm_group_label": "Taxol\u00ae (IV paclitaxel)", 
                "description": "Premedication, IV infusion on day 1 of 3-week cycle until progression,  unacceptable toxicity or withdrawal of informed concent", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Stomach Neoplasms", 
            "Cancer of Stomach", 
            "Gastric Cancer", 
            "Gastric Neoplasms", 
            "Neoplasms, Gastric", 
            "Neoplasms, Stomach", 
            "Stomach Cancer", 
            "paclitaxel", 
            "Taxol"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "location": [
            {
                "contact": {
                    "email": "daniel0602@hanmail.net", 
                    "last_name": "Myung Joo Kang, M.D.", 
                    "phone": "82-51-797-0001"
                }, 
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "612-896"
                    }, 
                    "name": "Inje University Haeundae Paik Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jkk21c@knu.ac.kr", 
                    "last_name": "Jong Gwang Kim, M.D, Ph.D.", 
                    "phone": "82-53-200-2623"
                }, 
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "zip": "702-210"
                    }, 
                    "name": "Kyungpook National University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "youngiee@ncc.re.kr", 
                    "last_name": "Young-Iee Park, M.D., Ph.D.", 
                    "phone": "82-31-920-1672"
                }, 
                "facility": {
                    "address": {
                        "city": "Goyang-si, Gyeonggi-do", 
                        "country": "Korea, Republic of", 
                        "zip": "410-769"
                    }, 
                    "name": "National Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ijchung@chonnam.ac.kr", 
                    "last_name": "Ik Joo Chung, M.D., Ph.D.", 
                    "phone": "82-61-379-7632"
                }, 
                "facility": {
                    "address": {
                        "city": "Jeollanam-do", 
                        "country": "Korea, Republic of", 
                        "zip": "519-763"
                    }, 
                    "name": "Chonnam National University Hwasun Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jwkim@snubh.org", 
                    "last_name": "Jin Won Kim, M.D", 
                    "phone": "82-31-787-7053"
                }, 
                "facility": {
                    "address": {
                        "city": "Seongnam-si, Gyeonggi-do", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sachoh@korea.ac.kr", 
                    "last_name": "Sang Cheul Oh, M.D., Ph.D.", 
                    "phone": "82-2-2626-3060"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "152-703"
                    }, 
                    "name": "Korea University Guro Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ykkang@amc.seoul.kr", 
                    "last_name": "Yoon-Koo Kang, M.D., Ph. D.", 
                    "phone": "82-2-3010-8771"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "RHA7655@yuhs.ac", 
                    "last_name": "Sun Young Rha, M.D., Ph.D.", 
                    "phone": "82-2-2228-8050"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }, 
                    "name": "Yonsei University Severance Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "chojy@yuhs.ac", 
                    "last_name": "Jae Yong Cho, M.D., Ph.D.", 
                    "phone": "82-2-2019-4363"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-720"
                    }, 
                    "name": "Yonsei University Gangnam Severance Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "y331@catholic.ac.kr", 
                    "last_name": "Young Seon Hong, M.D., Ph.D.", 
                    "phone": "82-2-2258-6042"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137-701"
                    }, 
                    "name": "Seoul St. Mary's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hematoma@skku.edu", 
                    "last_name": "Se Hoon Park, M.D., Ph.D.", 
                    "phone": "82-2-3410-1767"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kangsy01@ajou.ac.kr", 
                    "last_name": "Seok Yun Kang, M.D.", 
                    "phone": "82-31-219-4911"
                }, 
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "zip": "443-380"
                    }, 
                    "name": "Ajou University Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open, Multicenter Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol\u00ae in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression Free Survival (PFS) is defined as the time From date of randomization until the date of first documented progression or death, assessed up to 24 months.", 
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed until progression, an expected average of 4 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839773"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival (OS) is defined as the time from the date of inclusion to the date of death, regardless of the cause of death.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Until 6 months after the last participant is enrolled, assessed up to 24 months."
            }, 
            {
                "description": "Overall Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria.", 
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed every 6 weeks until progression, an expected average of 4 months."
            }, 
            {
                "description": "Number and Description of Adverse Events", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Daehwa Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daehwa Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}